Ensign Peak Advisors, Inc Vaxcyte, Inc. Transaction History
Ensign Peak Advisors, Inc
- $56.1 Billion
- Q3 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 546,835 shares of PCVX stock, worth $50.1 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
546,835
Previous 462,682
18.19%
Holding current value
$50.1 Million
Previous $34.9 Million
78.7%
% of portfolio
0.11%
Previous 0.06%
Shares
13 transactions
Others Institutions Holding PCVX
# of Institutions
354Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.05 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$1 Billion0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$910 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$796 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$449 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.43B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...